Bruce Han Ph.D. Cofounder and CEO | Bruce Nianhe Han, Ph.D., joined NewBio Therapeutics as CSO in 2013 to lead new drug discovery efforts. Prior to NewBio, Dr. Han served as executive director of medicinal chemistry in ShangPharma and led the integrated drug discovery teams. Before this, Dr. Han worked in Amgen for 12 years in different therapeutics areas, including oncology, metabolic diseases, inflammation, anti-viral agents and CNS. In addition, Dr. Han also has over ten years of antibody engineering and antibody-drug conjugate (ADC) discovery experience, and is an expert in antibody screening, site-specific linker design, and ADC drug discovery and development. With over 20 years in biopharmaceutical industry, Dr. Han has led teams to deliver many clinical candidates. Dr. Han has over 60 of international patent applications and peer-reviewed publications. Dr. Han received both BS in nuclear chemistry and MS in physical chemistry from Peking University, and a Ph.D. in organic Chemistry from Columbia University. He conducted postdoctoral research in antibody engineering in Dr. Richard Lerner's Lab, and postdoctoral research in synthetic organic chemistry and medicinal chemistry in Dr. Dale Boger's lab sequentially, both at the Scripps Research Institute, California, USA. |
| | Deqiang An Ph.D. Vice President
| Deqiang An, Ph.D., joined NewBio Therapeutics as Director of Chemistry in July, 2011. Dr. An built the Chemistry Department of the company, and led the team develop novel site-specific linkers, high-potency cytotoxic drugs, and coupling methodology for antibody-drug conjugates. Prior to NewBio, he served as a team leader in ShangPharma, leading the medicinal chemistry teams to provide CRO service to GSK. Dr. An has over ten of international patent applications and peer-reviewed publications. Dr. An received both B.S. in applied chemistry and MS in analytical chemistry from Jilin University, and received his Ph.D. in organic Chemistry from the University of Texas at Austin. He conducted postdoctoralresearch at MIT in Dr. Daniel G. Nocera’s lab and Dr. Alexander M. Klibanov's lab. |
|